Biopharma Financial Climate and Market Dynamics in 2023: Interview with David Dowling, Ropes & Gray
Recently, David Dowling, a senior lawyer at Ropes & Gray, has outlined his predictions for M&A in the European biotech sector in 2023 in his blog Why 2023 is set to be a blockbuster year for European biotech dealmaking.
Ropes & Gray is a global law firm with approximately 1,500 lawyers and legal professionals serving clients in major centers of business, finance, technology, and government. Since the company is quite active in the life sciences space and regularly publishes market research findings in private and public biotech markets, I was excited to ask David a number of questions about his reflections of 2022 market climate and what we can expect in the industry in 2023.
According to Ropes & Gray, 2022 has been a more downbeat year for fundraising. Valuations have fallen on public markets and the anticipated boom of dealmaking failed to materialise. However, there are a number of factors set to make 2023 a truly exceptional year for biotechs, whether in licensing, fundraising or M&A:
Topic: Biotech Ventures
